Navigation Links
Mexican Department of Public Health to Launch Screening for Papillomavirus, Cause of Cervical Cancer
Date:11/19/2008

World's First National Cervical Cancer Screening Program to Use QIAGEN Test

MEXICO CITY, Nov. 10 /PRNewswire/ --In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud) announced today that it is launching the first phase of a program that will offer free testing for human papillomavirus (HPV), the primary cause of cervical cancer, to all low-income women age 35-65. In the first phase of the screening program, expected to begin this week, 200,000 women in the lowest-income 125 counties will be offered the papillomavirus test along with the traditional Pap smear. Early next year, the pilot program will be expanded to include another 600,000 women in the 20 states with the highest death rate from cervical cancer. It is hoped that if the program goes well, the remaining eight Mexican states will join the program later in 2009.

"Every year, more than 9,000 Mexican women are diagnosed with cervical cancer and nearly half of them die. Yet this is an entirely preventable disease," said Peer Schatz, CEO of QIAGEN (Nasdaq: QGEN; Frankfurt, Prime Standard: QIA), the company that developed the digene(R)HPV Test, which will be used in the SSA's program and is the only such test approved by the U.S. Food and Drug Administration. "The Mexican government is taking a leadership role in Latin America, and the world, and QIAGEN is committed to joining with the SSA to assure that our advanced screening technology is accessible to women everywhere, no matter what their income level or social class."

Papillomavirus is a very common infection. In fact, the World Health Organization estimates that 11 percent of Mexican women carry cervical HPV at any given time. In the majority of women, the virus goes away or is suppressed by the body before it causes any problems. However, in others, the infection lingers and can cause abnormal cells to form. While the traditional Pap smear is usually able to find abnormal cells, it sometimes misses them. A study published in the Journal of the National Cancer Institute found that about one-third of invasive cervical cancers developed in women whose smears had appeared normal. In contrast, HPV testing detects the presence of the virus itself. In the national norms for cervical cancer prevention, which were updated in 2007, physicians are advised that they can supplement the Pap with HPV testing in women 25-65 for additional protection. If abnormal cells are diagnosed early, they can be removed before they develop into cervical cancer.

Worldwide, cervical cancer affects an estimated 500,000 women annually. It is estimated that 6 million women a year will be eligible for HPV testing through the Mexican public health system once the screening program becomes national. An additional 1 million women could access the test using private insurance.

"Reduction of health inequities among the Mexican people is a top priority of my administration, and a primary target is cervical cancer, a disease affecting the most vulnerable and poorest women in the country," said Mexican President Felipe Calderon. "It is the only cancer that could be eliminated if the most effective medical advances are accessible to everyone who needs them, and that includes HPV testing. While the new HPV vaccines will be important in the future, women today need the best screening possible."

About HPV and cervical cancer (theHPVtest.com and theHPVtest.com/espanol)

Worldwide, cervical cancer affects nearly 500,000 women annually and, after breast cancer, is the second-most-common malignancy found in women. Cervical cancer is caused by "high-risk" types of the human papillomavirus (HPV). It's estimated that 80 percent of women will get an HPV infection at some point in their lives. However, in most cases, the infection goes away or is suppressed by the body without causing problems. It is only infections that persist that can cause abnormal cells to form that may develop into cervical cancer if not detected and treated early. In Mexico, current estimates from the World Health Organization indicate that 12,516 women are diagnosed with cervical cancer every year, and 5,777 die from the disease.

About QIAGEN (qiagen.com)

QIAGEN NV is the leading global provider of sample and assay technologies, with its global headquarters in the Netherlands. Sample technologies are used to isolate and process DNA, RNA and proteins from biological samples such as blood or tissue, and assays make these isolated molecules visible to facilitate such vital activities as biological research and detection of disease. QIAGEN has developed and markets more than 500 products as well as instruments that make their use more efficient and accurate. The company provides its products to molecular diagnostics laboratories, academic researchers, pharmaceutical and biotechnology companies, and applied testing customers for purposes such as forensics, animal or food testing and pharmaceutical process control. QIAGEN's assay technologies include one of the broadest panels of molecular diagnostic tests available worldwide, including the only FDA-approved test for human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs more than 2,600 people in over 30 locations worldwide.


'/>"/>
SOURCE QIAGEN
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. FDA Warns of Dangers of Mexican Vanilla
2. MTF, Largest Tissue Bank, Donates Skin to Mexican Burn Victim
3. Mexican Peppers IDd as Salmonella Culprits
4. Move Over Margarita! Mexican Food has a New Dinner Partner
5. Genomma Lab Prices Initial Public Offering and Begins Trading on Mexican Stock Exchange
6. Women, Mexican-Americans at higher risk of ruptured brain aneurysm
7. Women, Mexican Americans at Higher Risk for Certain Stroke
8. Leading Travel Insurance Website Now Offers Mexican Auto Insurance to US and Canadian Travelers Going into Mexico
9. Genetics May Boost Mexican-Americans Risk for Alcoholism
10. UNICEF Readies to Assist Mexican Flood Victims
11. PA Health Department Reports Southeast Regions First Lab-Confirmed Influenza Case of the Season
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... ... December 08, 2016 , ... The ... the Undersea and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. ... safety. Only a few hospitals and facilities have earned this distinction. This is ...
(Date:12/8/2016)... ... December 08, 2016 , ... Russ ... announced the first national #QuackGivesBack campaign which supported local breast cancer organizations during ... franchise-wide Quack Gives Back initiative, and we’re very pleased with the ...
(Date:12/8/2016)... Pa. (PRWEB) , ... December 08, 2016 , ... ... Medicine Southern Chester County, a Property owned by an affiliate of Seavest, has ... square foot Penn Medicine Southern Chester County ambulatory care center (ACC) was named ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... CURE Media ... centers and advocacy groups, has aligned with Upstage Lung Cancer in efforts to combat ... the announcement, Michael J. Hennessy, Jr said, “CURE Media Group is honored to team ...
(Date:12/8/2016)... ... December 08, 2016 , ... David J. Dykeman , ... Greenberg Traurig, LLP, will speak at DeviceTalks West, Dec. 12, 2016, at the Fairmont ... and attorneys from the firm’s global Life Sciences & Medical Technology Group have been ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... OSAKA, Japan , Dec. 9, 2016 ... ; President & Representative Director, CEO: Dr. ... with amyotrophic lateral sclerosis (ALS) given edaravone intravenously in ... functional loss as measured by the ALS Functional Rating ... th International Symposium on ALS/MND in ...
(Date:12/9/2016)... 9, 2016  Axovant Sciences Ltd. (NYSE: ... focused on the treatment of dementia, today announced ... Phase 2b trial evaluating treatment with intepirdine (RVT-101), ... donepezil plus placebo in people with mild-to-moderate Alzheimer,s ... intepirdine to treatment was associated with reduced progression ...
(Date:12/8/2016)... 8, 2016 KEY FINDINGS ... Patient warming and ... blood during surgeries, lowering the risks of neurological disorders post ... SSIs. The patient warming systems can be segmented into convective ... in turn reduce the stay at hospitals thus, lowering the ...
Breaking Medicine Technology: